Democratic congressional report says Trump increased drugmaker holdings benefiting from Medicare exemptions

A congressional Democratic report released on October 16, 2026, reveals that Donald Trump's pharmaceutical stock holdings grew from $1.7 million in 2024 to $56.2 million by late 2025, boosted by investments in firms benefiting from Medicare price negotiation exemptions in Republicans' 2025 tax law. The White House maintains Trump's portfolio is independently managed without his input, while critics warn the policy could raise patient costs for key cancer drugs by $5,000 annually.

Growth of Donald Trump's pharmaceutical stock holdings

• ▪A report by congressional Democrats found up to $39.1 million of Donald Trump's pharmaceutical holdings at the end of 2025 was held in companies benefiting from Medicare price negotiation exemptions.
• ▪A Joint Economic Committee minority report found Donald Trump's pharmaceutical stock holdings grew from a maximum value of $1.7 million in 2024 to as much as $56.2 million at the end of 2025.
• ▪Donald Trump's investment portfolio continued trading pharmaceutical company stocks during the first eight months of 2026, adding up to $3.5 million in sector stock wealth.

White House response to ethics concerns

• ▪White House spokesperson Davis Ingle stated Donald Trump's stock portfolio is independently managed by third-party financial institutions, denying any conflict of interest or family influence over trades.
• ▪The White House repeatedly denied any ethics issues and accused Democrats of attempting to fabricate conflicts of interest.

Expansion of orphan drug exemptions and debate

• ▪Republicans' 2025 tax and spending law expanded exemptions for medications developed for rare diseases, delaying or excluding certain costly drugs from Medicare price negotiations.
• ▪Critics of the expanded orphan drug exemption argued it allows manufacturers of blockbuster medications to avoid Medicare price negotiations that lower costs for beneficiaries.
• ▪Supporters of expanding the orphan drug exemption argued that broader exemptions encourage pharmaceutical companies to develop new treatments for rare diseases.

Timing of stock purchases around legislation

• ▪Donald Trump's investment portfolio bought up to $950,000 in exempt pharmaceutical company stocks on July 1, 2025, the day the Senate passed the tax and spending bill.
• ▪Donald Trump's investment portfolio purchased as much as $1 million in AbbVie stock in August 2025 after Republicans' tax and spending bill became law.
• ▪Donald Trump's investment portfolio purchased up to $2.55 million in shares of pharmaceutical companies benefiting from exemptions on three dates prior to signing Republicans' tax and spending bill in July 2025.

Cancer drug holdings and costs

• ▪Donald Trump's investment portfolio includes stock in both Merck and Bristol Myers Squibb.
• ▪The Joint Economic Committee minority report estimated Medicare beneficiaries receiving cancer drugs Keytruda by Merck or Opdivo by Bristol Myers Squibb could pay roughly $5,000 more annually without negotiated prices.

Presidential asset management standards

• ▪Donald Trump placed his broader business interests in a trust managed by his sons, rejecting the blind trust or asset-liquidation practices used by recent predecessors.
• ▪All recent U.S. presidents dumped their stocks before taking office, invested in broadly diversified funds, or established blind trusts.